Funding for this research was provided by:
National Natural Science Foundation of China (81802669, 81501852, 61871294, 81472046 and 81772299, 11701385, 81872149)
Natural Science Foundation of Zhejiang Province (LR19C060001)
Natural Science Foundation of Beijing Municipality (JQ20032)
Fundamental Research Funds for Wenzhou Institute of University of Chinese Academy of Sciences (WIBEZD2017009-05)
Tsinghua University-Peking Union Medical College Hospital Initiative Scientific Research Program
CAMS Initiative Fund for Medical Sciences (2016-I2M-2-006 and 2017-I2M-2-001, 2016-I2M-3-003, 2016-I2M-1-001)
National Key Research and Development Program of China (2018YFC0910506)
CAMS Innovation Fund for Medical Sciences (2020-I2M-C&T-B-068)
Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
Received: 6 November 2020
Accepted: 9 February 2021
First Online: 19 February 2021
Ethics approval and consent to participate
: This study followed the criteria of REMARK (REporting recommendations for tumor MARKer prognostic studies) was reviewed and approved by the ethics committees of the Cancer Hospital of the Chinese Academy of Medical Sciences and Peking Union Medical College and the Harbin Medical University Cancer Hospital. Each participant provided written informed consent. This study was compliant with ethics committees for patient data release and act privacy.
: All the authors have read and approved the final manuscript for publication.
: The authors have no conflict of interest to declare.